Pharmaceutical Antitrust Enforcement Under Trump Administration: Trends, Developments and Updates
The bipartisan support for antitrust enforcement in the pharmaceutical industry implies Trump administration’s continued focus on the industry in 2017. Targets for antitrust enforcement include pharmaceutical companies’ conduct at the expiration of patent life, reverse payment settlements, and pharmaceutical pricing.
Thus, pharmaceutical companies should carefully watch the actions of the U.S. Department of Justice’s (DOJ) Antitrust Division and the Federal Trade Commission (FTC) to keep themselves abreast of potential dramatic regulatory shifts and, therefore, to be able to position themselves effectively.
In this LIVE Webcast, a panel of distinguished professionals and thought leaders will help pharmaceutical companies understand the important aspects of this significant topic. They will provide an in-depth discussion of the recent Pharmaceutical Antitrust Enforcement trends and developments under the Trump Administration. Speakers will also offer expert insights on best compliance practices.
Key topics include:
- Trump’s Antitrust Agency Leadership
- Top Targets for Antitrust Enforcement
- Notable Case Law
- Best Compliance Targets
William Diaz, Partner
McDermott Will & Emery LLP
Amanda Hamilton, Attorney
- Discuss President Trump’s statements regarding high drug prices, and the implications of those statements
- Learn what to expect from the federal antitrust agencies regarding pharmaceutical antitrust enforcement, this includes a discussion of current leadership at each agency, current enforcement efforts, and any signs of future enforcement efforts
- Understand the implications of Congress’s and FDA’s activity, including pending legislation, referrals to the FTC, and new regulation on pharmaceutical antitrust enforcement
Who Should Attend:
- Antitrust Lawyers
- Pharmaceutical and Healthcare Industries
- General Counsel in Life Sciences and Healthcare Industries
- Pharma/Healthcare Attorneys & Advisors
- Pharmaceutical Companies
- Other related/interested Professionals and Organizations
William (Will) Díaz litigates and counsels clients on antitrust cases, obtains Federal Trade Commission (FTC) and Department of Justice clearance on mergers, and defends clients in government investigations. Will has significant experience in the interplay between the antitrust and intellectual property laws and the issues that crossover into both areas, including standard-setting activities, patent pools, fair, reasonable and non-discriminatory (FRAND) licensing issues and patent misuse. He also has handled numerous litigations and transactions in the biotech, pharmaceutical and medtech industries. Prior to joining McDermott, Will was an attorney for the FTC, Bureau of Competition, investigating and analyzing mergers and anticompetitive trade practices.
William (Will) Díaz litigates and counsels clients on antitrust cases, obtains Federal Trade Commission (FTC) and Department of Justice clearance …
Amanda Hamilton is an antitrust associate in the Washington, D.C. office of Haug Partners. Her practice concentrates on antitrust litigation, government investigations and counseling.
Ms. Hamilton was a staff attorney at the FTC’s Bureau of Competition. She investigated, analyzed mergers and anticompetitive practices in a variety of industries, including pharmaceutical, manufacturing, energy and health care. Ms. Hamilton has experience in all phases of the FTC’s investigation process. She was an integral member of several litigation teams at the FTC. Her litigation experience includes: FTC v. Ardagh Group, S.A. (a merger challenge) and FTC v. Reckitt Benckiser Pharmaceuticals, Inc. (a subpoena enforcement action).
Ms. Hamilton is active in the American Bar Association’s Antitrust Section. She serves as co-editor of Health Care & Pharmaceutical Committee’s Health Care Chronicle and contributed to Antitrust Law Developments (8th ed., in progress).
Amanda Hamilton is an antitrust associate in the Washington, D.C. office of Haug Partners. Her practice concentrates on antitrust litigation, …
Print and review course materials
Method of Presentation:
Basic Knowledge in Pharmaceutical Antitrust
NASBA Field of Study:
Business Law - Technical
NY Category of CLE Credit:
Areas of Professional Practice
Unlock All The Knowledge and Credit You Need
Leading Provider of Online Continuing Education
It's As Easy as 1, 2, 3
Get Your 1-Year All Access Pass For Only $199
About McDermott Will & Emery LLP
Established in 1934 as a tax practice in Chicago, Illinois, McDermott has grown its core practices and offices around the globe. Today, we are a leading international law firm with nearly 1,100 lawyers practicing in 10 US offices, seven European offices, as well as in a strategic alliance with MWE China Law Offices in Asia. In addition, McDermott was one of the first Western law firms to open an office in Seoul. In the years to come, we will continue to expand geographically and enhance our existing practices and industry-focused practices and industry-focused strengths. We are committed to building from these strengths in order to best serve our clients and communities.
About Haug Partners LLP
Haug Partners is a full-service, national law firm that provides integrated multidisciplinary legal services for life science and technology companies. Our service offerings include: (i) Antitrust Litigation and Counseling; (ii) Commercial Litigation and Strategic Counseling; (iii) Due Diligence; (iv) FDA Compliance and Counseling; (v) Intellectual Property Enforcement; (vi) Intellectual Property Procurement and Strategy; (vii) International Trade Commission; (viii) Investigations, Compliance, and Risk Mitigation Services; (ix) Licensing and Transactions; and (x) Trademarks and Unfair Competition. With offices in New York, Washington, D.C., and Boston, and through relationships with firms in Germany, China, Japan, and other key international markets, Haug Partners has the resources, technical expertise, legal acumen, and business judgment to consistently deliver optimal outcomes for clients. The firm was founded in 1997 as Frommer Lawrence and Haug and adopted the Haug Partners name in March 2017.